FDA 블랙박스 경고: BUMETANIDE

먼저 결론

이 FDA 블랙박스 경고는 Bumetanide의 심각한 안전 위험을 빠르게 확인하기 위한 참고 정보입니다. 이 약을 복용 중이거나 새로 처방받았다면 임의로 시작·중단하지 말고, 처방 의사나 약사에게 탈수, 어지럼, 전해질 이상, 신장질환, 다른 이뇨제 병용 여부를 함께 알려 상담하세요.

블랙박스 경고

Bumetanide (BUMETANIDE) — AvPAK

WARNING Bumetanide is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion. Therefore, careful medical supervision is required, and dose and dosage schedule have to be adjusted to the individual patient's needs (see DOSAGE AND ADMINISTRATION ).

약물 상호작용

Drug Interactions Drugs with Ototoxic Potential (see WARNINGS ) . Especially in the presence of impaired renal function, the use of parenterally administered bumetanide in patients to whom aminoglycoside antibiotics are also being given should be avoided, except in life-threatening conditions. Drugs with Nephrotoxic Potential There has been no experience with the concurrent use of bumetanide with drugs known to have a nephrotoxic potential. Therefore, the simultaneous administration of these dru

주의사항

WARNINGS Volume and Electrolyte Depletion The dose of bumetanide should be adjusted to the patient's need. Excessive doses or too frequent administration can lead to profound water loss, electrolyte depletion, dehydration, reduction in blood volume and circulatory collapse with the possibility of vascular thrombosis and embolism, particularly in elderly patients. Hypokalemia Hypokalemia can occur as a consequence of bumetanide administration. Prevention of hypokalemia requires particular attenti

이 정보는 FDA 공공 데이터를 기반으로 하며, 의사/약사의 전문적 판단을 대체하지 않습니다.